{"answer":{"query":"xolair","resolved_as":"name","packages":9,"applications":["BLA103976"],"identity":{"application_numbers":["BLA103976"],"marketing_categories":["BLA"],"labelers":[{"text":"GENENTECH, INC.","untrusted":true}],"dosage_forms":[{"text":"INJECTION, SOLUTION","untrusted":true}],"marketing_start":{"earliest":"2003-06-20","latest":"2023-08-18","packages_with_a_start_date":7}},"label_history":{"events_total":20,"non_cmc_events":18,"counts_by_class":{"LABELING":9,"EFFICACY":8,"S":1},"cmc_events":2,"recent_non_cmc_events":[{"application":"BLA103976","submission_no":5253,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-08-06","documents":[{"type":"Letter","date":"2026-08-10","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/103976Orig1s5253ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-08-11","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103976s5253lbl.pdf","untrusted":true}}],"fact_id":"8897c48852c30664c653a0c1"},{"application":"BLA103976","submission_no":5245,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-02-16","documents":[{"type":"Label","date":"2024-02-16","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-02-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/103976Orig1s5245ltr.pdf","untrusted":true}}],"fact_id":"bfdd3e5a352831be0d9cf925"},{"application":"BLA103976","submission_no":5243,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-03-17","documents":[{"type":"Letter","date":"2023-03-20","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/103976Orig1s5243ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-05-03","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103976Orig1s5243lbl.pdf","untrusted":true}}],"fact_id":"60742d378723d3a2f1078aa6"},{"application":"BLA103976","submission_no":5238,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2021-04-09","documents":[{"type":"Label","date":"2021-04-12","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5238lbl.pdf","untrusted":true}},{"type":"Letter","date":"2021-04-13","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/103976Orig1s5238ltr.pdf","untrusted":true}}],"fact_id":"684a99d65bcb2260215f6604"},{"application":"BLA103976","submission_no":5235,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2020-11-30","documents":[{"type":"Label","date":"2020-12-01","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/103976s5235lbl.pdf","untrusted":true}},{"type":"Letter","date":"2020-12-02","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/103976Orig1s5235ltr.pdf","untrusted":true}}],"fact_id":"34daa99f6e81ec919f60803d"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"NOT_PROVIDED":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"BLA103976","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XOLAIR","untrusted":true},"form":{"text":"VIAL","untrusted":true},"strength":{"text":"150MG/VIAL","untrusted":true}},{"application":"BLA103976","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XOLAIR","untrusted":true},"form":{"text":"SYRINGE","untrusted":true},"strength":{"text":"150MG/ML","untrusted":true}},{"application":"BLA103976","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XOLAIR","untrusted":true},"form":{"text":"SYRINGE","untrusted":true},"strength":{"text":"75MG/0.5ML","untrusted":true}},{"application":"BLA103976","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"XOLAIR","untrusted":true},"form":{"text":"SYRINGE","untrusted":true},"strength":{"text":"300MG/2ML","untrusted":true}}]},"recalls":{"recalls_total":4,"counts_by_class":{"Class II":4},"packages_of_these_applications":7,"most_recent":[{"recall_number":"D-0571-2025","classification":"Class II","status":"Ongoing","report_date":"2025-08-13","recall_initiated":"2025-07-30","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.","untrusted":true},"packages_named":7,"fact_id":"f756dbf4c6a2eeacfb8e61f2"},{"recall_number":"D-0572-2025","classification":"Class II","status":"Ongoing","report_date":"2025-08-13","recall_initiated":"2025-07-30","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.","untrusted":true},"packages_named":7,"fact_id":"e52c7ff20c8ea04916f8ea27"},{"recall_number":"D-0650-2021","classification":"Class II","status":"Terminated","report_date":"2021-07-14","recall_initiated":"2021-06-09","recalling_firm":{"text":"Genentech Inc","untrusted":true},"reason":{"text":"Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.","untrusted":true},"packages_named":7,"fact_id":"d498023fd77838c54ca31a9c"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"OMALIZUMAB","untrusted":true},"recruiting_interventional_count":12,"not_yet_recruiting_count":1,"by_phase":{"PHASE4":4,"PHASE3":1,"PHASE1":1,"PHASE2":6},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06824649","title":{"text":"Biologics in Chronic Rhinosinusitis With Nasal Polyposis","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Medical University of South Carolina","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2026-06-03","link":{"text":"https://clinicaltrials.gov/study/NCT06824649","untrusted":true}},{"nct_id":"NCT07845552","title":{"text":"Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Johns Hopkins University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2026-10-19","link":{"text":"https://clinicaltrials.gov/study/NCT07845552","untrusted":true}},{"nct_id":"NCT07816328","title":{"text":"Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Novartis Pharmaceuticals","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-13","start_date":"2026-09-21","link":{"text":"https://clinicaltrials.gov/study/NCT07816328","untrusted":true}},{"nct_id":"NCT07356713","title":{"text":"A Study to Find a Suitable Dose of Exl-111 for Further Research","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Excellergy Inc.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-22","start_date":"2026-01-08","link":{"text":"https://clinicaltrials.gov/study/NCT07356713","untrusted":true}},{"nct_id":"NCT07059091","title":{"text":"Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Johns Hopkins University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-09-04","start_date":"2026-02-12","link":{"text":"https://clinicaltrials.gov/study/NCT07059091","untrusted":true}}],"fact_id":"041f46c7d59cb44a0b11fb6d"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Genentech/Roche Access Solutions","untrusted":true},"type":"manufacturer","url":"https://www.gene.com/patients/patient-foundation","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Omalizumab","untrusted":true},"brand":{"text":"Xolair","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":150601320.94,"claims":49179,"beneficiaries":6456,"average_spending_per_claim_usd":3062.3095415,"fact_id":"4085f0932fa53516d3f0b9ef"},{"year":2021,"gross_spending_usd":161212649.7,"claims":54013,"beneficiaries":6736,"average_spending_per_claim_usd":2984.7008998,"fact_id":"33ca816969518cc3ca6894cb"},{"year":2022,"gross_spending_usd":208230097.21,"claims":68699,"beneficiaries":8052,"average_spending_per_claim_usd":3031.0499019,"fact_id":"1efd5a695dbc47c40c95c618"},{"year":2023,"gross_spending_usd":254056608.93,"claims":79113,"beneficiaries":9161,"average_spending_per_claim_usd":3211.313045,"fact_id":"be884a86d20363d37e30f3e9"},{"year":2024,"gross_spending_usd":313118328.76,"claims":95356,"beneficiaries":11011,"average_spending_per_claim_usd":3283.6772595,"fact_id":"afe4d3d151a9c244918e99a6"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"biologic_status":{"products":[{"application":"BLA103976","status":"Reference","name":{"text":"Xolair","untrusted":true},"proper_name":{"text":"omalizumab","untrusted":true},"license_status":"Licensed","approval_date":"2003-06-20","reference_product":null,"interchangeable_date":null,"biosimilars_listed":0,"interchangeables_listed":1,"biosimilars":[],"interchangeables":[{"name":{"text":"Omlyclo","untrusted":true},"proper_name":{"text":"omalizumab-igec","untrusted":true},"bla_number":"761399","approval_date":"2025-03-07","interchangeable_date":"2025-03-07"}],"purple_book_version":"purplebook-2026-10","read_on":"2026-11-07T07:33:31.186Z","fact_id":"0ae04db544831b44e34263e7"}],"reading":"what the FDA Purple Book lists on its read date, a record and not a forecast of launch or substitution"},"payment_limit":{"codes":[{"hcpcs":"J2357","quarter":"2026Q4","effective":"October 1, 2026 through December 31, 2026","payment_limit_usd":45.687,"dosage_descriptor":{"text":"5 MG","untrusted":true},"packages_matched":7,"read_on":"2026-11-07T07:31:28.000Z","source_url":{"text":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","untrusted":true},"fact_id":"f900568bd37cdcfe79e28be2"}],"codes_total":1,"meaning":"a Medicare Part B payment ceiling for providers billing a HCPCS code, per dosage descriptor unit; not a price a patient pays, and the presence of a code does not indicate that Medicare covers a product"},"rems":{"programs":[{"application":"BLA103976","program":{"text":"Xolair","untrusted":true},"rems_id":"298","in_force":false,"released":true,"moved_to_shared_system":false,"has_etasu":false,"program_date":"2009-07-24","last_modified":"2011-12-22","source_page":"https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=298","other_programs":0,"read_on":"2026-11-07T20:05:28.959Z","fact_id":"54158373edb918eb5cf22fd3"}],"reading":"what the FDA REMS@FDA files tie to the application on the read date; it does not say which prescribers or pharmacies take part or whether a patient needs the program"},"medicaid_state_utilization":{"year":2025,"states_with_data":49,"all_states_medicaid_reimbursed_usd":206123212.42,"all_states_medicaid_paid_prescriptions":63848,"top_states":[{"state":"NY","medicaid_paid_prescriptions":7098,"medicaid_reimbursed_usd":23356297.97,"total_reimbursed_usd":23502061.54,"packages":4,"covers":"fee_for_service_only","fact_id":"1ed464d033fe342b69de2dc2"},{"state":"CA","medicaid_paid_prescriptions":6197,"medicaid_reimbursed_usd":21529168.79,"total_reimbursed_usd":21950424.47,"packages":4,"covers":"fee_for_service_only","fact_id":"c32ec418ae994be6c3e9fc84"},{"state":"NC","medicaid_paid_prescriptions":3835,"medicaid_reimbursed_usd":14599925.12,"total_reimbursed_usd":15149900.72,"packages":4,"covers":"fee_for_service_only","fact_id":"28af1b1a077e270012f3f141"},{"state":"PA","medicaid_paid_prescriptions":3336,"medicaid_reimbursed_usd":10369878.96,"total_reimbursed_usd":11600611.44,"packages":4,"covers":"fee_for_service_only","fact_id":"461033f37efa03be0e1b8790"},{"state":"FL","medicaid_paid_prescriptions":2694,"medicaid_reimbursed_usd":9152319.59,"total_reimbursed_usd":9514254.24,"packages":4,"covers":"fee_for_service_only","fact_id":"89b69707d0c15fd0ef0fe309"},{"state":"OH","medicaid_paid_prescriptions":2994,"medicaid_reimbursed_usd":9052203.99,"total_reimbursed_usd":9193479.43,"packages":4,"covers":"fee_for_service_only","fact_id":"75ba76888ec5e2bd5888a1c4"},{"state":"MI","medicaid_paid_prescriptions":3043,"medicaid_reimbursed_usd":9031795.77,"total_reimbursed_usd":9524810.25,"packages":4,"covers":"fee_for_service_only","fact_id":"0db5450c55402ff2c0a50852"},{"state":"VA","medicaid_paid_prescriptions":2832,"medicaid_reimbursed_usd":7400291.93,"total_reimbursed_usd":8145855.8,"packages":4,"covers":"fee_for_service_only","fact_id":"f569816661cbedb3f289a63a"},{"state":"MA","medicaid_paid_prescriptions":2299,"medicaid_reimbursed_usd":7105699.22,"total_reimbursed_usd":7759065.31,"packages":4,"covers":"fee_for_service_only","fact_id":"1fb3db033cf04219e08e424d"},{"state":"WI","medicaid_paid_prescriptions":2077,"medicaid_reimbursed_usd":6948257.85,"total_reimbursed_usd":7112007.48,"packages":4,"covers":"all_record_types","fact_id":"dab18fd6df0075a0610e045b"}],"unlabelled_state_code_xx":{"medicaid_paid_prescriptions":9896,"medicaid_reimbursed_usd":19383098.06,"note":"the source uses the code XX without defining it; it is reported here and never added to a state"},"built_from_facts":134,"facts_fee_for_service_only":65,"older_year_facts_not_used":41,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"136e4eabffd39af62a3e1277","field":"ndc.listing","entity":"ndc:50242004062"},{"fact_id":"001ad860a6874cb106a74bb4","field":"ndc.listing","entity":"ndc:50242021403"},{"fact_id":"378896763ba2a27ed9b5cd5d","field":"ndc.listing","entity":"ndc:50242021455"},{"fact_id":"8897c48852c30664c653a0c1","field":"drug.label_event","entity":"application:BLA103976"},{"fact_id":"bfdd3e5a352831be0d9cf925","field":"drug.label_event","entity":"application:BLA103976"},{"fact_id":"60742d378723d3a2f1078aa6","field":"drug.label_event","entity":"application:BLA103976"},{"fact_id":"684a99d65bcb2260215f6604","field":"drug.label_event","entity":"application:BLA103976"},{"fact_id":"34daa99f6e81ec919f60803d","field":"drug.label_event","entity":"application:BLA103976"},{"fact_id":"fa2d84e1211116b1fe4a13b8","field":"drug.marketing_status","entity":"application:BLA103976"},{"fact_id":"4b88f8cf318e54f3b68ce6e4","field":"drug.marketing_status","entity":"application:BLA103976"},{"fact_id":"344eab08601cfede5b2128af","field":"drug.marketing_status","entity":"application:BLA103976"},{"fact_id":"1bfaa90308d2a87fab4afd19","field":"drug.marketing_status","entity":"application:BLA103976"},{"fact_id":"f756dbf4c6a2eeacfb8e61f2","field":"ndc.recall","entity":"ndc:50242021503"},{"fact_id":"e52c7ff20c8ea04916f8ea27","field":"ndc.recall","entity":"ndc:50242021455"},{"fact_id":"d498023fd77838c54ca31a9c","field":"ndc.recall","entity":"ndc:50242021555"},{"fact_id":"041f46c7d59cb44a0b11fb6d","field":"drug.trial_access","entity":"drug:omalizumab"},{"fact_id":"4085f0932fa53516d3f0b9ef","field":"drug.partd_spending","entity":"drug:omalizumab|xolair"},{"fact_id":"33ca816969518cc3ca6894cb","field":"drug.partd_spending","entity":"drug:omalizumab|xolair"},{"fact_id":"1efd5a695dbc47c40c95c618","field":"drug.partd_spending","entity":"drug:omalizumab|xolair"},{"fact_id":"be884a86d20363d37e30f3e9","field":"drug.partd_spending","entity":"drug:omalizumab|xolair"},{"fact_id":"afe4d3d151a9c244918e99a6","field":"drug.partd_spending","entity":"drug:omalizumab|xolair"},{"fact_id":"0ae04db544831b44e34263e7","field":"drug.biologic_status","entity":"application:BLA103976"},{"fact_id":"b3630ef2bf73b8da4e72136a","field":"drug.biologic_status","entity":"application:BLA761399"},{"fact_id":"f900568bd37cdcfe79e28be2","field":"drug.asp_price","entity":"hcpcs:J2357"},{"fact_id":"54158373edb918eb5cf22fd3","field":"drug.rems","entity":"application:BLA103976"},{"fact_id":"1ed464d033fe342b69de2dc2","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022755:NY"},{"fact_id":"c32ec418ae994be6c3e9fc84","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:CA"},{"fact_id":"28af1b1a077e270012f3f141","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:NC"},{"fact_id":"461033f37efa03be0e1b8790","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022755:PA"},{"fact_id":"89b69707d0c15fd0ef0fe309","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:FL"},{"fact_id":"75ba76888ec5e2bd5888a1c4","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:OH"},{"fact_id":"0db5450c55402ff2c0a50852","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022755:MI"},{"fact_id":"f569816661cbedb3f289a63a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:VA"},{"fact_id":"1fb3db033cf04219e08e424d","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022701:MA"},{"fact_id":"dab18fd6df0075a0610e045b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:50242022755:WI"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"generic_entry:BLA103976","reason":"no generic-entry fact for this application: no patent or exclusivity is listed for it in the Orange Book edition read, so no date is stated"},{"code":"NO_DATA","field":"generic_entry","reason":"no application of this drug has a generic-entry fact; no date is stated"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}